Navigation Links
Four of Molecular Medicine's Thought Leaders will Keynote at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
Date:11/21/2008

Cambridge Healthtech Institute’s (CHI) flagship event, the Molecular Medicine Tri-Conference (February 24-27, 2009) will feature four of molecular medicine’s thought leaders as Plenary Keynotes.

Needham, MA (PRWEB) November 21, 2008 -— Cambridge Healthtech Institute’s (CHI) flagship event, the Molecular Medicine Tri-Conference (February 24-27, 2009) will feature four of molecular medicine’s thought leaders as Plenary Keynotes.

David Ewing Duncan, Chief Correspondent of NPR Talk’s “Biotech Nation” and best-selling Author of “Masterminds”, will offer his insights during his presentation “Brave New Age of Personalized Medicine”, scheduled Thursday, February 26, 2009 at 2:25pm.

Jay M. Tenenbaum, Ph.D, Chairman and Chief Scientist of CollabRx, Inc., will deliver a keynote presentation to discuss “Using Molecular Medicine to do Therapeutic Development in the Network Age”, on Wednesday, February 25, 2009 at 8:55am. Dr. Tenenbaum is a leader in internet commerce and tells the personal and timely story of transforming healthcare and accelerating therapy development through virtual biotechs.

Michael J. Yaszemski, M.D., Ph.D., Brigadier General of the United States Air Force Reserves and Professor of Orthopedic Surgery and Biomedical Engineering, College of Medicine, Mayo Clinic, is breaking new ground in spinal cord nerve regeneration. Dr. Yaszemski’s presentation, “Tissue Engineering Strategies for Musculoskeletal Regenerative Medicine in Civilian and Military Applications”, is on Thursday, February 26, 2009 at 7:30am.

James A. Wells, Ph.D., Professor and Chair of Pharmaceutical Chemistry, and Professor of Cellular & Molecular Pharmacology at the University of California, San Francisco is a pioneer in the hot area of fragment-based screening. Dr. Wells’ Keynote on “Engineering Cells to Death” is scheduled Thursday, February 26, 2009 at 1:40pm.
The Molecular Medicine Tri-Conference keynotes will all be held at the Moscone Convention Center in San Francisco, California.

About the Molecular Medicine Tri-Conference

The Molecular Medicine Tri-Conference is the flagship of event of CHI’s portfolio of 100+ events. Now in its sixteenth year, the Molecular Medicine Tri-Conference is the most comprehensive discovery, diagnostic and development event worldwide. For 2009, the Tri-Conference was developed around the theme of Shaping Future Medicine. Although the term ‘molecular medicine’ has been around for over 20 years, only now do researchers have the means to practice the art. Scientists now have the knowledge at their disposal to improve diagnosis and enhance the efficacy and safety of molecular therapeutics, elements that are essential for future commercial success.

The 2009 conference, you will learn to:

  • Design precision diagnostic tools and identify disease biomarkers (MOLECULAR DIAGNOSTICS)
  • Reduce late-stage attrition through translational biomarkers, more predictive models, and earlier proof-of-concept studies (TRANSLATIONAL MEDICINE)
  • Use genomic, proteomic and pathway information to identify the best drug targets (CANCER PROFILING AND PATHWAYS)
  • Optimize the design of therapeutic agents, including small- and large-molecules, (MEDICINAL CHEMISTRY, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
  • Explore cell-based therapeutics, including the latest advances in stem cell therapies
  • (STEM CELL THERAPIES, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
  • Map intricate pathways and identify drug intervention points
  • (CANCER PROFILING AND PATHWAYS)
  • Develop safer therapeutics that can flourish in the market with reduced chance of adverse events (PRECLINICAL DRUG SAFETY)
  • Generate effective business and diversification strategies to maximize progress with problematic targets and diseases ( EXECUTIVE SUMMIT)
  • Leverage informatics tools and strategies to improve R&D success (IT TRACK)

Last year's event had record-setting attendance that brought together 3000 delegates from over 40 countries. For questions about the Molecular Medicine Tri-Conference, call Cambridge Healthtech Institute at 781-972-5400; or visit www.Tri-Conference.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

www.chicoporate.com

Press Inquiries Please Contact:
Tracey Fielding
Cambridge Healthtech Institute
Ph. (781) 972-5429

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1651694.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: